Article

How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment.

Department of Experimental Medicine, Sapienza University of Rome, Italy.
American journal of clinical oncology (impact factor: 2.21). 12/2011; 34(6):625-7. DOI:10.1097/COC.0b013e3181f94596 pp.625-7
Source: PubMed

ABSTRACT Resistance to anthracyclines is responsible for treatment failure in most patients with metastatic breast cancer. According to recent studies, the expression of specific drug transporters (MRPs) on circulating tumor cells is predictive of prognosis in different cancer types. We observed that patients whose circulating tumor cells expressed MRP1 and MRP2, two drug-export pumps responsible for anthracyclines efflux, who received conventional anthracyclines had a significantly shorter time to progression compared with patients sharing same characteristics who received non pegylated liposomal doxorubicin (P < 0.005). These results may highlight a new appealing role of the liposomal doxorubicin formulation, not only because of its reduced cardiac toxicity but especially referring to its theoretical efficacy in anthracycline-resistant breast cancer patients.

0 0
 · 
0 Bookmarks
 · 
55 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

anthracycline-resistant breast cancer patients
 
circulating tumor cells
 
conventional anthracyclines
 
different cancer types
 
drug-export pumps responsible
 
liposomal doxorubicin formulation
 
metastatic breast cancer
 
new appealing role
 
non pegylated liposomal doxorubicin
 
reduced cardiac toxicity
 
shorter time
 
specific drug transporters
 
tumor cells